Detail akcie VivoSim Labs Inc online

Business Summary: VivoSim Labs, Inc. is a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. The Company offers partners liver and intestinal toxicology insights using its new approach methodologies (NAM) models. The Company offers liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development. It uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. The Company's 3D human tissue platform is multifaceted. The Company has expertise in 3D organoids, such as spheroids, and has made advances in proprietary cell culture techniques including ratios, components and conditions.
Financial Summary: BRIEF: For the six months ended 30 September 2025, VivoSim Labs Inc revenues decreased 6% to $65K. Net loss decreased 9% to $5.4M. Revenues reflect Products and services decrease from $16K to $0K. Lower net loss reflects Research and development expensesBala decrease of 20% to $1.8M (expense), General and administrative decrease of 52% to $124K (expense), Interest income increase of 63% to $168K (income).